Evidence map›Paper›PMID 37692653›Full record

ArticleCureus2023

A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections.

Cecilia Costiniuk, Anne-Marie Bourgault, Chelsea Maedler-Kron, Liane Feldman

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Cecilia CostiniukMedicine, Research Institute of the McGill University Health Centre, Montreal, CAN.
Anne-Marie BourgaultInfectious Diseases/Medical Microbiology, Royal Victoria Hospital/McGill University Health Centre, Montreal, CAN.
Chelsea Maedler-KronLaboratory Medicine/Pathology, Royal Victoria Hospital/McGill University Health Centre, Montreal, CAN.
Liane FeldmanSurgery/General Surgery, Montreal General Hospital/McGill University Health Centre, Montreal, ASM.
Montreal General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enfuvirtide was the first marketed fusion inhibitor that worked by binding to glycoprotein 41 of the HIV envelope, preventing the conformational changes required for HIV fusion with CD4+ T cells. Due to its novel mechanisms of action, it was frequently used in the past as part of regimens for the indication of multi-class-resistant HIV until newer oral agents emerged. Here, we describe the case of a 40-year-old man who used enfuvirtide injections from 2012 to 2017 inclusive for multi-class-resistant HIV until he presented in 2021 with an abscess overlying a right lower quadrant mass requiring drainage via pigtail. Congo red stain of the tissue showed positive apple green birefringence on amorphous material after polarization, enabling the diagnosis of enfuvirtide-induced amyloidosis. The patient experienced significant improvement following surgical excision of the cysts and nodules. This case demonstrates that sequelae of injection site reactions can persist for many years following the cessation of enfuvirtide injections.

Indexed as

amyloidosisenfuvirtidehivinjection site reactionsskin nodules

Identifiers

PMID37692653
PMCPMC10483575
OpenAlexW4385664209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.